These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

600 related items for PubMed ID: 20719211

  • 1. Cancers attributable to human papillomavirus infection.
    Grulich AE, Jin F, Conway EL, Stein AN, Hocking J.
    Sex Health; 2010 Sep; 7(3):244-52. PubMed ID: 20719211
    [Abstract] [Full Text] [Related]

  • 2. Comprehensive control of human papillomavirus infections and related diseases.
    Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, Stern PL, Stanley M, Arbyn M, Poljak M, Cuzick J, Castle PE, Schiller JT, Markowitz LE, Fisher WA, Canfell K, Denny LA, Franco EL, Steben M, Kane MA, Schiffman M, Meijer CJ, Sankaranarayanan R, Castellsagué X, Kim JJ, Brotons M, Alemany L, Albero G, Diaz M, de Sanjosé S, authors of the ICO Monograph ‘Comprehensive Control of HPV Infections and Related Diseases’ Vaccine Volume 30, Supplement 5, 2012.
    Vaccine; 2013 Dec 29; 31 Suppl 5():F1-31. PubMed ID: 24331745
    [Abstract] [Full Text] [Related]

  • 3. Comprehensive control of human papillomavirus infections and related diseases.
    Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, Stern PL, Stanley M, Arbyn M, Poljak M, Cuzick J, Castle PE, Schiller JT, Markowitz LE, Fisher WA, Canfell K, Denny LA, Franco EL, Steben M, Kane MA, Schiffman M, Meijer CJ, Sankaranarayanan R, Castellsagué X, Kim JJ, Brotons M, Alemany L, Albero G, Diaz M, de Sanjosé S, Authors of the ICO Monograph ‘Comprehensive Control of HPV Infections and Related Diseases’ Vaccine Volume 30, Supplement 5, 2012.
    Vaccine; 2013 Nov 22; 31 Suppl 8(0 8):I1-31. PubMed ID: 24229716
    [Abstract] [Full Text] [Related]

  • 4. Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels.
    Jemal A, Simard EP, Dorell C, Noone AM, Markowitz LE, Kohler B, Eheman C, Saraiya M, Bandi P, Saslow D, Cronin KA, Watson M, Schiffman M, Henley SJ, Schymura MJ, Anderson RN, Yankey D, Edwards BK.
    J Natl Cancer Inst; 2013 Feb 06; 105(3):175-201. PubMed ID: 23297039
    [Abstract] [Full Text] [Related]

  • 5. Monitoring the control of human papillomavirus (HPV) infection and related diseases in Australia: towards a national HPV surveillance strategy.
    Brotherton JM, Kaldor JM, Garland SM.
    Sex Health; 2010 Sep 06; 7(3):310-9. PubMed ID: 20719220
    [Abstract] [Full Text] [Related]

  • 6. Beyond cervical cancer: burden of other HPV-related cancers among men and women.
    Chaturvedi AK.
    J Adolesc Health; 2010 Apr 06; 46(4 Suppl):S20-6. PubMed ID: 20307840
    [Abstract] [Full Text] [Related]

  • 7. Epidemiological dynamic modeling of human papillomavirus-related diseases to assess vaccination strategies in Argentina.
    Borracci RA, Segal SV, Méndez JH.
    Medicina (B Aires); 2018 Apr 06; 78(5):315-328. PubMed ID: 30285924
    [Abstract] [Full Text] [Related]

  • 8. Cytology and cervical cancer surveillance in an era of human papillomavirus vaccination.
    Budd AC, Sturrock CJ.
    Sex Health; 2010 Sep 06; 7(3):328-34. PubMed ID: 20719223
    [Abstract] [Full Text] [Related]

  • 9. Burden of human papillomavirus infection and related diseases in Israel.
    Shavit O, Roura E, Barchana M, Diaz M, Bornstein J.
    Vaccine; 2013 Nov 22; 31 Suppl 8():I32-41. PubMed ID: 24229717
    [Abstract] [Full Text] [Related]

  • 10. Prevention of Human Papillomavirus Infection. Beyond Cervical Cancer: A Brief Review.
    Medeiros R, Vaz S, Rebelo T, Figueiredo-Dias M.
    Acta Med Port; 2020 Mar 02; 33(3):198-201. PubMed ID: 32130098
    [Abstract] [Full Text] [Related]

  • 11. Targeting human papillomavirus to reduce the burden of cervical, vulvar and vaginal cancer and pre-invasive neoplasia: establishing the baseline for surveillance.
    Nygård M, Hansen BT, Dillner J, Munk C, Oddsson K, Tryggvadottir L, Hortlund M, Liaw KL, Dasbach EJ, Kjær SK.
    PLoS One; 2014 Mar 02; 9(2):e88323. PubMed ID: 24505474
    [Abstract] [Full Text] [Related]

  • 12. Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions.
    Serrano B, de Sanjosé S, Tous S, Quiros B, Muñoz N, Bosch X, Alemany L.
    Eur J Cancer; 2015 Sep 02; 51(13):1732-41. PubMed ID: 26121913
    [Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.
    Võrno T, Lutsar K, Uusküla A, Padrik L, Raud T, Reile R, Nahkur O, Kiivet RA.
    Vaccine; 2017 Nov 01; 35(46):6329-6335. PubMed ID: 28899625
    [Abstract] [Full Text] [Related]

  • 14. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.
    Muñoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, Garcia PJ, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Huh WK, Joura EA, Kurman RJ, Majewski S, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan JT, Lupinacci LC, Giacoletti KE, Sings HL, James MK, Hesley TM, Barr E, Haupt RM.
    J Natl Cancer Inst; 2010 Mar 03; 102(5):325-39. PubMed ID: 20139221
    [Abstract] [Full Text] [Related]

  • 15. Cost-effectiveness of the prophylactic HPV vaccine: an application to the Netherlands taking non-cervical cancers and cross-protection into account.
    Luttjeboer J, Westra TA, Wilschut JC, Nijman HW, Daemen T, Postma MJ.
    Vaccine; 2013 Aug 20; 31(37):3922-7. PubMed ID: 23806241
    [Abstract] [Full Text] [Related]

  • 16. US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines.
    Saraiya M, Unger ER, Thompson TD, Lynch CF, Hernandez BY, Lyu CW, Steinau M, Watson M, Wilkinson EJ, Hopenhayn C, Copeland G, Cozen W, Peters ES, Huang Y, Saber MS, Altekruse S, Goodman MT, HPV Typing of Cancers Workgroup.
    J Natl Cancer Inst; 2015 Jun 20; 107(6):djv086. PubMed ID: 25925419
    [Abstract] [Full Text] [Related]

  • 17. Trends in Risks for Second Primary Cancers Associated With Index Human Papillomavirus-Associated Cancers.
    Suk R, Mahale P, Sonawane K, Sikora AG, Chhatwal J, Schmeler KM, Sigel K, Cantor SB, Chiao EY, Deshmukh AA.
    JAMA Netw Open; 2018 Sep 07; 1(5):e181999. PubMed ID: 30646145
    [Abstract] [Full Text] [Related]

  • 18. The impact of Germany's human papillomavirus immunization program on HPV-related anogenital diseases: a retrospective analysis of claims data from statutory health insurances.
    Goodman E, Reuschenbach M, Viering T, Luzak A, Greiner W, Hampl M, Jacob C.
    Arch Gynecol Obstet; 2024 Nov 07; 310(5):2639-2646. PubMed ID: 39230793
    [Abstract] [Full Text] [Related]

  • 19. EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease.
    Arbyn M, de Sanjosé S, Saraiya M, Sideri M, Palefsky J, Lacey C, Gillison M, Bruni L, Ronco G, Wentzensen N, Brotherton J, Qiao YL, Denny L, Bornstein J, Abramowitz L, Giuliano A, Tommasino M, Monsonego J.
    Int J Cancer; 2012 Nov 01; 131(9):1969-82. PubMed ID: 22623137
    [Abstract] [Full Text] [Related]

  • 20. Cancer incidence in Germany attributable to human papillomavirus in 2013.
    Buttmann-Schweiger N, Deleré Y, Klug SJ, Kraywinkel K.
    BMC Cancer; 2017 Oct 16; 17(1):682. PubMed ID: 29037233
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.